NeuBase Therapeutics, Inc. (NBSE)
NASDAQ: NBSE · IEX Real-Time Price · USD
0.421
0.00 (0.00%)
Apr 24, 2024, 4:30 PM EDT - Market closed
Company Description
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.
The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.
Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene.
NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Todd P. Branning |
Contact Details
Address: 350 Technology Drive Pittsburgh, Pennsylvania 15219 United States | |
| Phone | 412-763-3350 |
| Website | neubasetherapeutics.com |
Stock Details
| Ticker Symbol | NBSE |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001173281 |
| CUSIP Number | 64132K102 |
| ISIN Number | US64132K2015 |
| Employer ID | 46-5622433 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd P. Branning | Interim Chief Executive Officer, Chief Financial Officer and Secretary |
| Dr. Dietrich A. Stephan Ph.D. | Founder, President and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | 8-K | Current Report |
| Mar 25, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 17, 2024 | 8-K | Current Report |
| Dec 28, 2023 | 8-K | Current Report |
| Dec 28, 2023 | 424B3 | Prospectus |